Efficacy, safety and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase 2 correlative study.

CONCLUSIONS: Axitinib achieved durable disease control with a favorable safety profile in heavily pretreated NPC patients.
PMID: 29301831 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 4, 2018 Category: Cancer & Oncology Authors: Hui EP, Ma BBY, Loong H, Mo F, Li L, King AD, Wang K, Ahuja AT, Chan CM, Hui CW, Wong CH, Chan AT Tags: Clin Cancer Res Source Type: research